He has received over fifteen research grants on a number of hematology related subjects and his work has been published in many noted medical journals. Dr. Tulpule is a member of the LAC+USC Medical Center’s Internal Review Board and has a role in determining the ethical implications of the center’s research studies. His dedication to ethical practices also includes a membership of USC Norris Comprehensive Cancer Center’s Patient’s Rights Committee.
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry Acta Haematol. 2019 Jul 17; 1-11. . View in PubMed
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Cancer. 2019 May 01; 125(9):1507-1517. . View in PubMed
Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib J Oncol Pharm Pract. 2019 Apr; 25(3):699-702. . View in PubMed
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Cancer. 2019 Jan 29. . View in PubMed
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma J Clin Oncol. 2017 Nov 01; 35(31):3538-3546. . View in PubMed
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States Cancer. 2017 Apr 01; 123(7):1174-1183. . View in PubMed
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States Clin Lymphoma Myeloma Leuk. 2017 04; 17(4):193-200. . View in PubMed
Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib J Oncol Pharm Pract. 2017 Jan 01; 1078155217745710. . View in PubMed
p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study Am J Clin Pathol. 2014 Apr; 141(4):593-604. . View in PubMed
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047 J Clin Oncol. 2013 Jan 01; 31(1):58-64. . View in PubMed
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Lancet Oncol. 2010 Dec; 11(12):1149-59. . View in PubMed
Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy Cancer. 2010 Aug 15; 116(16):3969-77. . View in PubMed
Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma Blood. 2010 Jul 15; 116(2):297-305. . View in PubMed
KSHV-induced notch components render endothelial and mural cell characteristics and cell survival Blood. 2010 Jan 28; 115(4):887-95. . View in PubMed
Bendamustine therapy in chronic lymphocytic leukemia Expert Opin Pharmacother. 2009 Jul; 10(10):1687-98. . View in PubMed
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma J Clin Oncol. 2008 Sep 20; 26(27):4473-9. . View in PubMed
Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies Cancer. 2006 Oct 15; 107(8):1909-17. . View in PubMed
Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma Clin Lymphoma Myeloma. 2006 Jul; 7(1):59-64. . View in PubMed
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy J Clin Oncol. 2006 Apr 10; 24(11):1712-9. . View in PubMed
Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy J Clin Oncol. 2005 Nov 20; 23(33):8477-82. . View in PubMed
Multidrug resistance in AIDS-related lymphoma Curr Opin Oncol. 2005 Sep; 17(5):466-8. . View in PubMed
AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy J Clin Oncol. 2005 Jul 01; 23(19):4430-8. . View in PubMed
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team J Clin Oncol. 2005 Feb 10; 23(5):990-8. . View in PubMed
Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium Blood. 2005 Feb 01; 105(3):1310-8. . View in PubMed
Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response J Clin Oncol. 2004 Jul 01; 22(13):2662-70. . View in PubMed
Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study Invest New Drugs. 2004 Jan; 22(1):63-8. . View in PubMed
Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma Cancer. 2002 Jul 01; 95(1):147-54. . View in PubMed
Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection Cancer. 2002 Mar 01; 94(5):1500-6. . View in PubMed
Multidrug resistance (MDR-1) expression in AIDS-related lymphomas Leuk Res. 2002 Feb; 26(2):121-7. . View in PubMed
High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma J Acquir Immune Defic Syndr. 2001 Dec 15; 28(5):416-21. . View in PubMed
Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma Clin Cancer Res. 2001 Sep; 7(9):2693-702. . View in PubMed
Clinical aspects and management of AIDS-related Kaposi's sarcoma Eur J Cancer. 2001 Jul; 37(10):1288-95. . View in PubMed
Incidence and management of AIDS-related lymphoma Oncology (Williston Park). 2001 May; 15(5):629-39; discussion 639-40, 645-6. . View in PubMed
Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma Ann Oncol. 2001 Apr; 12(4):457-62. . View in PubMed
Evolving characteristics of AIDS-related lymphoma Blood. 2000 Dec 15; 96(13):4084-90. . View in PubMed
Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist Blood. 2000 Nov 01; 96(9):3188-94. . View in PubMed
Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149) J Acquir Immune Defic Syndr. 2000 Aug 15; 24(5):444-50. . View in PubMed
Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma J Clin Oncol. 2000 Feb; 18(4):716-23. . View in PubMed
AIDS-related lymphoma Blood Rev. 1999 Sep; 13(3):147-50. . View in PubMed
Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma J Clin Oncol. 1999 Jun; 17(6):1876-83. . View in PubMed
Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma Cancer. 1998 Dec 01; 83(11):2370-6. . View in PubMed
Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma J Clin Oncol. 1998 Oct; 16(10):3369-74. . View in PubMed
Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma Curr Opin Oncol. 1998 Sep; 10(5):413-21. . View in PubMed
AIDS-Related malignancies Prim Care. 1998 Jun; 25(2):473-82. . View in PubMed
Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma J Natl Cancer Inst. 1997 Dec 03; 89(23):1797-802. . View in PubMed
Treatment of epidemic (AIDS-related) Kaposi's sarcoma Curr Opin Oncol. 1997 Sep; 9(5):433-9. . View in PubMed
Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial J Clin Oncol. 1997 Mar; 15(3):1094-103. . View in PubMed
Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma Ann Oncol. 1997 Jan; 8(1):79-83. . View in PubMed
The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma N Engl J Med. 1996 Oct 24; 335(17):1261-9. . View in PubMed
Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphomaEffect on human immunodeficiency virus and serum interleukin-6 levels over time. Cancer. 1996 Aug 01; 78(3):517-26. . View in PubMed
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin J Clin Oncol. 1995 Apr; 13(4):996-1003. . View in PubMed
Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study Cancer Chemother Pharmacol. 1995; 37(1-2):32-8. . View in PubMed
All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study Leukemia. 1994; 8 Suppl 3:S26-32. . View in PubMed
Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance Invest New Drugs. 1994; 12(3):197-206. . View in PubMed
